Drug Profile
Progesterone intravenous - BHR Pharma
Alternative Names: BHR-100Latest Information Update: 25 Dec 2021
Price :
$50
*
At a glance
- Originator BHR Pharma
- Class Hormonal contraceptives; Hormonal replacements; Infertility therapies; Pregnenediones; Small molecules
- Mechanism of Action Apoptosis inhibitors; GABA modulators; Glutamate antagonists; Interleukin 1 beta inhibitors; Interleukin 6 inhibitors; Lipid peroxidation inhibitors; Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Brain injuries
Most Recent Events
- 01 Mar 2014 BHR Pharma complete the global phase III SyNAPSe trial for Brain injuries in USA, Argentina, China, Europe, Israel, Malaysia, Russia, Singapore, Taiwan and Thailand (NCT01143064)
- 03 Sep 2013 BHR Pharma completes enrolment in the global phase III SyNAPSe trial for Brain injuries (NCT01143064)
- 13 Feb 2013 Progesterone intravenous - BHR Pharma receives Orphan Drug status for Brain injuries in European Union